Company intelligence / Profile preview

Five Prime Therapeutics, Inc.

South San Francisco, California, United States of Americaorpha.net ↗

Ownership: Private
Employees: ~134
Development stage: Phase 3

Overview

Phase 2 FIGHT trial showed bemarituzumab plus chemotherapy reduced risk of death by 42% versus chemotherapy alone in FGFR2b-positive, first-line advanced gastric or GEJ cancer patients. Final analysis showed median OS of 19.2 months versus 13.5 months (HR=0.77)[6]

Therapeutic areas: Oncology
Modalities: Antibodies
Industry: Biotech

Drug pipeline

1 asset

bemarituzumab

Phase 3

Indications: Gastric cancer, Gastroesophageal junction cancer

Partnerships

Bristol-Myers SquibbZai Lab (Shanghai) Co., Ltd.Galaxy Biotech, LLCBioWa, Inc.Lonza Sales AGSeagen (Seattle Genetics)

Beyond the preview

Go deeper on Five Prime Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Five Prime Therapeutics, Inc..

Explore the full profile